# | Title | Journal | Year | Citations |
---|
1 | The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria | Allergy: European Journal of Allergy and Clinical Immunology | 2018 | 1,008 |
2 | The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update | Allergy: European Journal of Allergy and Clinical Immunology | 2014 | 912 |
3 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial | Lancet Oncology, The | 2018 | 751 |
4 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial | Lancet Oncology, The | 2018 | 469 |
5 | Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy | Journal of Allergy and Clinical Immunology | 2013 | 461 |
6 | The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria | Allergy: European Journal of Allergy and Clinical Immunology | 2022 | 392 |
7 | Update of Immune Events in the Murine Contact Hypersensitivity Model: Toward the Understanding of Allergic Contact Dermatitis | Journal of Investigative Dermatology | 2013 | 303 |
8 | Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control | Journal of Allergy and Clinical Immunology | 2014 | 268 |
9 | Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man | Frontiers in Immunology | 2015 | 222 |
10 | The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases | Frontiers in Immunology | 2016 | 213 |
11 | Development and construct validation of the angioedema quality of life questionnaire | Allergy: European Journal of Allergy and Clinical Immunology | 2012 | 182 |
12 | Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition | European Journal of Cancer | 2017 | 162 |
13 | International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency | Allergy: European Journal of Allergy and Clinical Immunology | 2017 | 153 |
14 | The global burden of chronic urticaria for the patient and society* | British Journal of Dermatology | 2021 | 150 |
15 | Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial | Lancet Oncology, The | 2021 | 150 |
16 | Development, validation, and initial results of the Angioedema Activity Score | Allergy: European Journal of Allergy and Clinical Immunology | 2013 | 147 |
17 | Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study | Allergy: European Journal of Allergy and Clinical Immunology | 2019 | 136 |
18 | RhoA as a Key Regulator of Innate and Adaptive Immunity | Cells | 2019 | 130 |
19 | Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma | European Journal of Cancer | 2020 | 130 |
20 | High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria | Acta Dermato-Venereologica | 2011 | 110 |
21 | Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study | | 2019 | 108 |
22 | Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study | British Journal of Dermatology | 2020 | 104 |
23 | Inflammatory Monocytes Determine Endothelial Nitric-oxide Synthase Uncoupling and Nitro-oxidative Stress Induced by Angiotensin II | Journal of Biological Chemistry | 2014 | 96 |
24 | The Angioedema Quality of Life Questionnaire (AE‐QoL) – assessment of sensitivity to change and minimal clinically important difference | Allergy: European Journal of Allergy and Clinical Immunology | 2016 | 92 |
25 | Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial | Journal of Allergy and Clinical Immunology | 2017 | 92 |
26 | The Urticaria Activity Score—Validity, Reliability, and Responsiveness | Journal of Allergy and Clinical Immunology: in Practice | 2018 | 78 |
27 | Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma | European Journal of Cancer | 2017 | 76 |
28 | Methods report on the development of the 2013 revision and update of the EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria | Allergy: European Journal of Allergy and Clinical Immunology | 2014 | 75 |
29 | Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management | European Journal of Cancer | 2019 | 75 |
30 | Omalizumab is effective in symptomatic dermographism—results of a randomized placebo-controlled trial | Journal of Allergy and Clinical Immunology | 2017 | 73 |
31 | Prevalence, predictors and comorbidity of dry skin in the general population | Journal of the European Academy of Dermatology and Venereology | 2019 | 72 |
32 | β2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease | International Journal of Molecular Sciences | 2020 | 71 |
33 | ARIA guideline 2019: treatment of allergic rhinitis in the German health system | Allergologie Select | 2019 | 70 |
34 | Responsiveness and minimal important difference of the urticaria control test | Journal of Allergy and Clinical Immunology | 2017 | 68 |
35 | Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis | Cancer Immunology, Immunotherapy | 2016 | 62 |
36 | Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria | Allergy: European Journal of Allergy and Clinical Immunology | 2011 | 61 |
37 | Substance P Is Upregulated in the Serum of Patients with Chronic Spontaneous Urticaria | Journal of Investigative Dermatology | 2014 | 61 |
38 | A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria | Journal of Allergy and Clinical Immunology | 2016 | 60 |
39 | Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab | Journal of Allergy and Clinical Immunology | 2010 | 59 |
40 | Machine Learning and Its Application in Skin Cancer | International Journal of Environmental Research and Public Health | 2021 | 56 |
41 | Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria | Annals of Allergy, Asthma and Immunology | 2010 | 55 |
42 | Erythema nodosum‐like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature | Journal of the European Academy of Dermatology and Venereology | 2015 | 55 |
43 | Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients | | 2020 | 55 |
44 | Treatment options for leishmaniasis | Clinical and Experimental Dermatology | 2022 | 54 |
45 | Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H 1 ‐antihistamine dose escalation | British Journal of Dermatology | 2012 | 53 |
46 | Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients | Annals of Oncology | 2017 | 53 |
47 | Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial | Nature Medicine | 2021 | 52 |
48 | Omalizumab rapidly improves angioedema‐related quality of life in adult patients with chronic spontaneous urticaria: X‐ACT study data | Allergy: European Journal of Allergy and Clinical Immunology | 2018 | 51 |
49 | Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients | European Journal of Cancer | 2017 | 50 |
50 | Comparison and interpretability of the available urticaria activity scores | Allergy: European Journal of Allergy and Clinical Immunology | 2018 | 50 |